BioCentury

12:29 AM GMT, Aug 28, 2012
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Clinical News

Merck updates CV pipeline

Merck & Co. Inc. (NYSE:MRK) provided an update on its cardiovascular programs Monday, including a reanalysis of data from the Phase III DEFINE trial of anacetrapib using a

Read the full 281 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.